Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Director departure
Appointed director
|
|
Kintara Therapeutics, Inc. (DMPI)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 10/10/2023 |
8-K
| Quarterly results |
| 09/26/2023 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing Interact... |
| 06/30/2023 |
8-K
| Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders... |
| 06/02/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 05/25/2023 |
8-K
| Submission of Matters to a Vote of Security Holders Interactive Data |
| 05/11/2023 |
8-K
| Quarterly results|
Docs:
|
"SUMMARY OF FINANCIAL RESULTS FOR FISCAL YEAR 2023 THIRD QUARTER ENDED MARCH 31, 2023 As of March 31, 2023, Kintara had cash and cash equivalents of approximately $3.0 million. For the three months ended March 31, 2023, Kintara reported a net loss of approximately $3.3 million, or $1.94 per share, compared to a net loss of approximately $5.4 million, or $5.45 per share, for the three months ended March 31, 2022. For the nine months ended March 31, 2023, Kintara reported a net loss of approximately $11.3 million, or $7.32 per share, compared to a net loss of approximately $17.2 million, or $22.39 per share, for the nine months ended March 31, 2022. The decreased net losses for the three and nine months ended March 31, 2023 compared to the three and nine months ended March 31, 2022 was largel..." |
|
| 05/09/2023 |
8-K
| Submission of Matters to a Vote of Security Holders Interactive Data |
| 03/10/2023 |
8-K
| Regulation FD Disclosure Interactive Data |
| 02/14/2023 |
8-K
| Quarterly results|
Docs:
|
"SUMMARY OF FINANCIAL RESULTS FOR FISCAL YEAR 2023 SECOND QUARTER ENDED DECEMBER 31, 2022 As of December 31, 2022, Kintara had cash and cash equivalents of approximately $4.9 million. For the three months ended December 31, 2022, Kintara reported a net loss of approximately $3.5 million, or $2.10 per share, compared to a net loss of approximately $5.9 million, or $6.07 per share, for the three months ended December 31, 2021. For the six months ended December 31, 2022, Kintara reported a net loss of approximately $8.1 million, or $5.42 per share, compared -1- to a net loss of approximately $11.9 million, or $17.30 per share, for the six months ended December 31, 2021. The decreased net losses for the three and six months ended December 31, 2022 compared to the three and six months ended Dece..." |
|
| 12/05/2022 |
8-K
| Quarterly results |
| 11/30/2022 |
8-K
| Quarterly results |
| 11/14/2022 |
8-K
| Material Modifications to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Yea... |
| 11/09/2022 |
8-K
| Quarterly results |
| 10/19/2022 |
8-K
| Quarterly results |
| 09/27/2022 |
8-K
| Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits I...|
Docs:
|
"SUMMARY OF FINANCIAL RESULTS FOR FISCAL YEAR ENDED JUNE 30, 2022 -1- At June 30, 2022, Kintara had cash and cash equivalents of approximately $11.8 million. During the year ended June 30, 2022, the Company completed two registered direct offerings for aggregate net proceeds to the Company of approximately $21.6 million. For the year ended June 30, 2022, Kintara reported a net loss of approximately $22.7 million, or $0.52 per share, compared to a net loss of approximately $38.3 million, or $1.60 per share, for the year ended June 30, 2021. The decreased net loss for the year ended June 30, 2022 compared to the year ended June 30, 2021 was largely due to the recognition of $16.1 million of non-cash expenses related to the acquisition of in-process research and development costs associated wi..." |
|
| 08/03/2022 |
8-K
| Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits Interactive Data|
Docs:
|
"PURCHASE AGREEMENT PURCHASE AGREEMENT , dated as of August 2, 2022, by and between KINTARA THERAPEUTICS, INC., a Nevada corporation , LINCOLN PARK CAPITAL FUND, LLC, an Illinois limited liability company . WHEREAS: Subject to the terms and conditions set forth in this Agreement, the Company wishes to sell to the Investor, and the Investor wishes to buy from the Company, up to Twenty Million Dollars of the Company's common stock, par value $0.001 per share . The shares of Common Stock to be purchased hereunder are referred to herein as the "Purchase Shares." NOW THEREFORE, in consideration of the mutual covenants contained in this Agreement, and for other good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, the Company and the Investor hereby a...",
"REGISTRATION RIGHTS AGREEMENT REGISTRATION RIGHTS AGREEMENT , dated as of August 2, 2022, by and between KINTARA THERAPEUTICS, INC., a Nevada corporation , and LINCOLN PARK CAPITAL FUND, LLC, an Illinois limited liability company . Capitalized terms used herein and not otherwise defined herein shall have the respective meanings set forth in the Purchase Agreement by and between the parties hereto, dated as of the date hereof . WHEREAS: A. Upon the terms and subject to the conditions of the Purchase Agreement, the Company has agreed to issue to the Investor, and the Investor has agreed to purchase, up to Twenty Million Dollars of the Company's common stock, par value $0.001 per share , pursuant to the Purchase Agreement , and the Company has agreed to issue to the Investor 1,630,191 shares ...",
"Kintara Therapeutics Enters Into Equity Purchase Agreement for Up to $20 Million with Lincoln Park Capital" |
|
| 06/22/2022 |
8-K
| Quarterly results |
| 06/16/2022 |
8-K
| Quarterly results |
| 06/03/2022 |
8-K
| Quarterly results |
| 05/24/2022 |
8-K
| Quarterly results |
| 05/13/2022 |
8-K
| Quarterly results |
| 04/18/2022 |
8-K
| Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year Interactive Data|
Docs:
|
"AMENDMENT NO. 2 TO THE AMENDED BYLAWS OF KINTARA THERAPEUTICS, INC. This Amendment No. 2 to the Bylaws of Kintara Therapeutics, Inc., a Nevada corporation , as amended to date is made as of this 13th day of April, 2022. 1. The Bylaws are hereby amended by replacing existing Section 6 of Article I of the Bylaws, in its entirety with the following: “6. Except where otherwise provided by law, the Articles of Incorporation, these Bylaws or the rules of any applicable stock exchange, the holders of one-third of the voting power of the capital stock issued and outstanding and entitled to vote, present in person or represented by proxy, shall constitute a quorum for the transaction of business at all meetings of the shareholders. Where a separate vote by a class or series or classes or ser..." |
|
| 04/13/2022 |
8-K
| Entry into a Material Definitive Agreement Interactive Data|
Docs:
|
"COMMON STOCK PURCHASE WARRANT KINTARA THERAPEUTICS, INC. Warrant Shares: _______ Initial Exercise Date: April 14, 2022 THIS COMMON STOCK PURCHASE WARRANT certifies that, for value received, _____________ or its assigns is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after April 14, 2022 and on or prior to 5:00 p.m. on April 14, 2027 but not thereafter, to subscribe for and purchase from Kintara Therapeutics, Inc., a Nevada corporation , up to ______ shares of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2. Section 1. Definitions. Capitalized terms used and not otherwise defined herein shall have the meanings set f...",
"PLACEMENT AGENT COMMON STOCK PURCHASE WARRANT kintara therapeutics, inc. Warrant Shares: _______ Initial Exercise Date: October 14, 2022 Initial Issue Date: April 14, 2022 THIS PLACEMENT AGENT COMMON STOCK PURCHASE WARRANT certifies that, for value received, _____________ or its assigns is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after October 14, 2022 and on or prior to 5:00 p.m. on October 14, 2026 but not thereafter, to subscribe for and purchase from Kintara Therapeutics, Inc., a Nevada corporation , up to ______ shares of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2. This Warrant is being issued pursuan...",
"Letter re: Report on Form 8-K for Kintara Therapeutics, Inc.",
"Letter re: Kintara Therapeutics, Inc. Registered Direct Offering",
"ARTICLE I.",
"9920 Pacific Heights Blvd, Suite 150 San Diego, CA 92121 Attn: Robert E. Hoffman, Chief Executive Officer",
"Kintara Announces $8.6 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules SAN DIEGO, April 12, 2022 /PRNewswire/ -- Kintara Therapeutics, Inc. , a biopharmaceutical company focused on the development of new solid tumor cancer therapies today announced that it has entered into definitive agreements with institutional investors for the purchase and sale of 16,226,416 shares of the Company's common stock and warrants to purchase 16,226,416 shares of the Company's common stock at a combined purchase price of $0.53 per Share and related Warrant in a registered direct offering priced at-the-market under Nasdaq rules for gross proceeds of approximately $8.6 million, before deducting fees and other offering expenses. The Warrants will have an exercise price of $0.41 per sha..." |
|
| 02/11/2022 |
8-K
| Quarterly results |
| 02/08/2022 |
8-K
| Quarterly results |
| 01/18/2022 |
8-K
| Other Events Interactive Data |
| 01/10/2022 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 12/06/2021 |
8-K
| Quarterly results |
| 11/15/2021 |
8-K
| Quarterly results |
| 11/12/2021 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 10/29/2021 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 09/29/2021 |
8-K
| Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits I... |
| 09/27/2021 |
8-K
| Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits Interactive Data |
| 09/07/2021 |
8-K
| Quarterly results |
|
|
|